CA19-9 Pancreatic Cancer Antigen

£79

CA 19-9 is most appropriately used in monitoring disease progression or effectiveness of treatment once diagnosis of the tumour has been made and serum concentrations have been shown to be raised prior to treatment (Lewis negative individuals do not express CA 19-9).

CA 19-9 has been shown to be raised in:

Pancreatic adenoncarcinomas (most)
Gastric carcinomas (50%)
Colorectal carcinomas (30%)

CA 19-9 should not be used for non-GIT malignancy.

Biomarkers:

CA19-9

Estimated turnaround time:

7 Working Days

Note:

This service is only available to the age of 13 and above.

During booking, only a £30 deposit is required, which will be deducted from the total cost. The remaining payment will be collected at a later stage.

Any cancellation, rescheduling, or missed appointment within 48 hours of the scheduled time will result in the loss of the £30 deposit. If you wish to reschedule, a new £30 deposit will be required to secure the new appointment.